Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP).
Journal
Blood cancer journal
ISSN: 2044-5385
Titre abrégé: Blood Cancer J
Pays: United States
ID NLM: 101568469
Informations de publication
Date de publication:
07 Oct 2024
07 Oct 2024
Historique:
received:
26
06
2024
accepted:
25
09
2024
revised:
22
09
2024
medline:
8
10
2024
pubmed:
8
10
2024
entrez:
7
10
2024
Statut:
epublish
Résumé
MRD2STOP is a pragmatic trial evaluating maintenance therapy cessation guided by measurable residual disease (MRD) negativity in multiple myeloma (MM). Eligible patients had previous MRD < 10
Identifiants
pubmed: 39375362
doi: 10.1038/s41408-024-01156-x
pii: 10.1038/s41408-024-01156-x
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
170Informations de copyright
© 2024. The Author(s).
Références
Munshi NC, Avet-Loiseau H, Anderson KC, Neri P, Paiva B, Samur M, et al. A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma. Blood Adv. 2020;4:5988–99.
doi: 10.1182/bloodadvances.2020002827
pubmed: 33284948
pmcid: 7724898
Gay F, Musto P, Rota-Scalabrini D, Bertamini L, Belotti A, Galli M, et al. Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial. Lancet Oncol. 2021;22:1705–20.
doi: 10.1016/S1470-2045(21)00535-0
pubmed: 34774221
Avet-Loiseau H, San-Miguel J, Casneuf T, Iida S, Lonial S, Usmani SZ, et al. Evaluation of sustained minimal residual disease negativity with daratumumab-combination regimens in relapsed and/or refractory multiple myeloma: analysis of POLLUX and CASTOR. J Clin Oncol. 2021;39:1139–49.
doi: 10.1200/JCO.20.01814
pubmed: 33513030
pmcid: 8078259
San-Miguel J, Avet-Loiseau H, Paiva B, Kumar S, Dimopoulos MA, Facon T, et al. Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE. Blood. 2022;139:492–501.
doi: 10.1182/blood.2020010439
pubmed: 34269818
pmcid: 8796656
Perrot A, Lauwers-Cances V, Corre J, Robillard N, Hulin C, Chretien M-L, et al. Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. Blood. 2018;132:2456–64.
doi: 10.1182/blood-2018-06-858613
pubmed: 30249784
pmcid: 6284215
Diamond B, Korde N, Lesokhin AM, Smith EL, Shah U, Mailankody S, et al. Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial. Lancet Haematol. 2021;8:e422–e432.
doi: 10.1016/S2352-3026(21)00130-7
pubmed: 34048681
Paiva B, Puig N, Cedena M-T, Rosiñol L, Cordón L, Vidriales M-B et al. Measurable residual disease by next-generation flow cytometry in multiple myeloma. JCO. 2019.
McCarthy PL, Holstein SA, Petrucci MT, Richardson PG, Hulin C, Tosi P, et al. Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis. J Clin Oncol. 2017;35:3279–89.
doi: 10.1200/JCO.2017.72.6679
pubmed: 28742454
pmcid: 5652871
Jackson GH, Davies FE, Pawlyn C, Cairns DA, Striha A, Collett C, et al. Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2019;20:57–73.
doi: 10.1016/S1470-2045(18)30687-9
pubmed: 30559051
pmcid: 6318225
Richardson PG, Jacobus SJ, Weller EA, Hassoun H, Lonial S, Raje NS, et al. Triplet therapy, transplantation, and maintenance until progression in myeloma. N. Engl J Med. 2022;387:132–47.
doi: 10.1056/NEJMoa2204925
pubmed: 35660812
pmcid: 10040899
Jasielec J, Kubicki T, Raje N, Vij R, Reece D, Berdeja JG et al. Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma. Blood. 2020. https://doi.org/10.1182/blood.2020007522 .
D’Agostino M, Bertuglia G, Rota-Scalabrini D, Belotti A, Morè S, Corradini P, et al. Predictors of unsustained measurable residual disease negativity in patients with multiple myeloma. Blood. 2024;143:592–6.
doi: 10.1182/blood.2023022080
pubmed: 38048557
Guerrero C, Puig N, Cedena M-T, Calasanz M-J, Gutierrez NC, Fernandez M, et al. Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma. Blood. 2024;143:597–603.
doi: 10.1182/blood.2023022083
pubmed: 38048552
Kvam AK, Fayers PM, Wisloff F. Responsiveness and minimal important score differences in quality-of-life questionnaires: a comparison of the EORTC QLQ-C30 cancer-specific questionnaire to the generic utility questionnaires EQ-5D and 15D in patients with multiple myeloma. Eur J Haematol. 2011;87:330–7.
doi: 10.1111/j.1600-0609.2011.01665.x
pubmed: 21668504
Sully K, Trigg A, Bonner N, Moreno-Koehler A, Trennery C, Shah N, et al. Estimation of minimally important differences and responder definitions for EORTC QLQ-MY20 scores in multiple myeloma patients. Eur J Haematol. 2019;103:500–9.
doi: 10.1111/ejh.13316
pubmed: 31444815
pmcid: 6852250
Yu Y, Brown Wade N, Hwang AE, Nooka AK, Fiala MA, Mohrbacher A, et al. Variability in cytogenetic testing for multiple myeloma: a comprehensive analysis from across the United States. JCO Oncol Pract. 2020;16:e1169–e1180.
doi: 10.1200/JOP.19.00639
pubmed: 32469686
pmcid: 7564132
Notarfranchi L, Zherniakova A, Lasa M, Puig N, Cedena MT, Martinez-Lopez J, et al. Ultra-sensitive assessment of measurable residual disease (MRD) in peripheral blood (PB) of multiple myeloma (MM) patients using bloodflow. Blood. 2022;140:2095–7.
doi: 10.1182/blood-2022-167382
Rosiñol L, Oriol A, Ríos R, Blanchard MJ, Jarque I, Bargay J, et al. Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma. Blood. 2023;142:1518–28.
doi: 10.1182/blood.2022019531
pubmed: 37506339
Costa LJ, Chhabra S, Medvedova E, Dholaria BR, Schmidt TM, Godby KN et al. Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial. Lancet Haematol. 2023. https://doi.org/10.1016/S2352-3026(23)00236-3 .
Dytfeld D, Wróbel T, Jamroziak K, Kubicki T, Robak P, Walter-Croneck A, et al. Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol. 2023;24:139–50.
doi: 10.1016/S1470-2045(22)00738-0
pubmed: 36642080
pmcid: 10337122
Rodríguez-Otero P, Moreau P, Dimopoulos MA, Beksac M, Perrot A, Broijl A, et al. Daratumumab (DARA) + bortezomib/lenalidomide/dexamethasone (VRd) in transplant-eligible (TE) patients (pts) with newly diagnosed multiple myeloma (NDMM): analysis of minimal residual disease (MRD) in the PERSEUS trial. JCO. 2024;42:7502.
doi: 10.1200/JCO.2024.42.16_suppl.7502
Caraux A, Klein B, Paiva B, Bret C, Schmitz A, Fuhler GM, et al. Circulating human B and plasma cells. Age-associated changes in counts and detailed characterization of circulating normal CD138− and CD138+ plasma cells. Haematologica. 2010;95:1016–20.
doi: 10.3324/haematol.2009.018689
pubmed: 20081059
pmcid: 2878802
Rasche L, Chavan SS, Stephens OW, Patel PH, Tytarenko R, Ashby C, et al. Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing. Nat Commun. 2017;8:268.
doi: 10.1038/s41467-017-00296-y
pubmed: 28814763
pmcid: 5559527
Derman BA, Jakubowiak AJ. Moving toward a cure in multiple myeloma: eradication of measurable residual disease. Adv Oncol. 2022;2:159–69.
doi: 10.1016/j.yao.2022.02.012